Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CorMedix Inc.
  6. Summary
    CRMD   US21900C3088

CORMEDIX INC.

(CRMD)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
3.830 USD   -4.73%
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2500 Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 3000 Value Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Dynamic Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
3.53(c) 3.56(c) 3.59(c) 4.02(c) 3.83 Last
254 599 242 657 154 770 565 328 334 165 Volume
+2.32% +0.85% +0.84% +11.98% -4.73% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 0,64 M - -
Net income 2022 -36,5 M - -
Net cash position 2022 118 M - -
P/E ratio 2022 -4,62x
Yield 2022 -
Sales 2023 24,6 M - -
Net income 2023 -37,5 M - -
Net cash position 2023 78,2 M - -
P/E ratio 2023 -6,06x
Yield 2023 -
Capitalization 157 M 157 M -
EV / Sales 2022 62,3x
EV / Sales 2023 3,21x
Nbr of Employees 30
Free-Float 98,3%
More Financials
Company
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is on the development of its lead product candidate, DefenCath, for commercialization in the United States. The DefenCath/Neutrolin is an anti-infective solution, a formulation of taurolidine... 
Read more
Sector
Pharmaceuticals
Calendar
08/16Earnings Release
More about the company
Ratings of CorMedix Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about CORMEDIX INC.
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2500 Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 3000 Value Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Dynamic Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 3000 Growth Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Growth Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2000 Value Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2500 Growth Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell Small Cap Comp Growth Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 3000E Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 3000E Value Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 3000E Growth Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 3000 Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell Small Cap Completeness Index
CI
06/24CORMEDIX INC.(NASDAQGM : CRMD) dropped from Russell 2500 Value Index
CI
More news
News in other languages on CORMEDIX INC.
05/12CorMedix Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
05/12CorMedix Inc. annonce des changements de direction
04/07CorMedix Inc. annonce la formation d'un nouveau conseil consultatif scientifique
03/29Le quatrième trimestre de CorMedix dépasse les estimations et prévoit des fonds suffisa..
03/29Earnings Flash (CRMD) CORMEDIX annonce un revenu de 56 397 $ pour le quatrième trimestr..
More news
Analyst Recommendations on CORMEDIX INC.
More recommendations
Chart CORMEDIX INC.
Duration : Period :
CorMedix Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CORMEDIX INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 4,02 $
Average target price 22,00 $
Spread / Average Target 447%
EPS Revisions
Managers and Directors
Joseph Todisco Chief Executive Officer & Director
Mathew T. David Chief Financial Officer & Executive Vice President
Myron Lawrence Kaplan Chairman
Antony E. Pfaffle Secretary & Chief Scientific Officer
Elizabeth Masson-Hurlburt Executive VP-Clinical & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
CORMEDIX INC.-11.65%157
MERCK KGAA-29.07%73 175
KYOWA KIRIN CO. LTD.-2.71%12 061
SK BIOPHARMACEUTICALS CO., LTD.-22.94%4 527
BETTA PHARMACEUTICALS CO., LTD.-23.84%3 770
YUHAN CORPORATION-9.82%2 941